Peking University People's Hospital: Sarcoma trials
The registry lists 14 Sarcoma studies with Peking University People's Hospital as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 6Phase 3 1No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing SarcomaRecruitingNCT06340204Phase 1
- Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis AssessmentActive, not recruitingNCT06850506
- The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis DeterminationActive, not recruitingNCT06751251
- Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' ResistanceCompletedNCT06202599
- Irinotecan and Anlotinib for Epithelioid SarcomaWithdrawnNCT05656222Not applicable
- TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN LossStatus unknownNCT04690725Phase 1/2
- Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue SarcomaStatus unknownNCT03880695Phase 2
- Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in BoneCompletedNCT03742063
- Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label UseCompletedNCT03491371Not applicable
- Anlotinib and Irinotecan for Ewing SarcomaStatus unknownNCT03416517Phase 1/2
- Irinotecan and Temozolomide for Ewing SarcomaStatus unknownNCT03359005Phase 2
- Clinical Evaluation for Sarcoma Originated From BoneStatus unknownNCT03358992
- Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue SarcomaWithdrawnNCT03342300Phase 2/3
- Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter TrialWithdrawnNCT03104335Phase 2